演題詳細

ポスター / Poster

ポスター 32 (Poster 32) :悪性リンパ腫:治療

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
磯部 泰司 (Yasushi Isobe):1
1:聖マリアンナ医科大学 血液・腫瘍内科
 
前へ戻る

Examination of auto-PBSCT for high risk and relapsed /refractory malignant lymphoma

演題番号 : PS-1-241

安藤 佐知子 (Sachiko Ando):1、前森 雅世 (Masayo Maemori):1、酒井 基 (Hajime Sakai):1、安藤 精章 (Seisho Ando):1

1:Dept of Hematology, Teine Keijinkai Hospital, Sapporo, Japan

 

High dose chemotherapy and auto-PBSCT (HDT-ASCT) is an important element of the treatment for patients with relapsed and refractory lymphoma, and also partially effective for patients with high risk 1st CR. We reviewed 20 patients transplanted between March 2003 and March 2013 in our institution. Median age was 54yr (25-69). 13 patients were B-cell lymphoma (indolent lymphoma 2, aggressive lymphoma 11), 6 were T-cell (PTCL-NOS 5, Primary cutaneous T-cell lymphoma 1), and 1 was Hodgkin lymphoma. The conditioning regimen was MCVC in 14, LEED in 4, M-BEAM in 2. Disease status at the transplantation was CR, 11(1st CR 6, 2nd CR 4, 3rd CR 1), PR, 9 (1st PR 6, 2nd PR 3). IPI classification L&LI were 9; H&HI were 11. There was no TRM, only one patient died because of suspected second malignancy (Colon cancer). The 5yr OS and RFS of the whole group was 62.0% and 55.5% in median observation period 46 months. On univariate analysis of prognostic factors, RFS and OS were not affected by age(≦60, ≧61), T-cell/B-cell phenotype, IPI. The disease status before transplantation was the only significant prognostic factor in determining OS (p=0.025) and RFS (p=0.012). HDT-ACST is feasible for patients with CR, including >=2nd CR as consolidation therapy, and tolerable.

前へ戻る